Abstracts tagged "safety and sleep"

Abstract Number: 1974 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Pregabalin for Fibromyalgia in a Population of Chinese Patients: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
Xiao Zhang¹, Huji Xu², Zhiyi Zhang³, Yang Li⁴, Lynne Pauer⁵, Shanmei Liao⁶, Gaiping Xu⁷ and Fengchun Zhang⁸, ¹Guangdong General Hospital, Guangdong, China, Guangdong, China, ²Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China, ³The First Affiliated Hospital of Harbin Medical University, Harbin, China, Harbin, China, ⁴The Second Affiliated Hospital of Harbin Medical University, Harbin, China, Harbin, China, ⁵Pfizer, Groton, CT, USA, Groton, CT, ⁶Pfizer (China) Statistics Department, Global Innovative Pharma Business, Shanghai, China, Shanghai, China, ⁷Pfizer (China) Clinical Development, Global Innovative Pharma Business, Beijing, China, Beijing, China, ⁸Peking Union Medical College Hospital, Beijing, China
Background/Purpose: Global trial data demonstrate the efficacy of pregabalin for the treatment of pain associated with fibromyalgia (FM), but there are currently no approved medical…
Abstract Number: 52 • 2016 ACR/ARHP Annual Meeting
Pregabalin Dose-Response for Sleep Quality and Pain Response in Fibromyalgia: A Post-Hoc Analysis of Three Randomized Trials
Andrew Clair¹, Ed Whalen¹, Neal Thomas¹ and Lynne Pauer², ¹Pfizer, New York, NY, ²Pfizer, Groton, CT
Background/Purpose: Pregabalin is often administered for treatment of fibromyalgia (FM) at daily doses lower than approved by the US Food and Drug Administration (starting dose…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].